JPH0470939B2 - - Google Patents
Info
- Publication number
- JPH0470939B2 JPH0470939B2 JP59127279A JP12727984A JPH0470939B2 JP H0470939 B2 JPH0470939 B2 JP H0470939B2 JP 59127279 A JP59127279 A JP 59127279A JP 12727984 A JP12727984 A JP 12727984A JP H0470939 B2 JPH0470939 B2 JP H0470939B2
- Authority
- JP
- Japan
- Prior art keywords
- component
- membrane
- phb
- pore size
- microporous membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012982 microporous membrane Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 229920000620 organic polymer Polymers 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical group CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 5
- 229920000728 polyester Polymers 0.000 claims description 4
- 229920001169 thermoplastic Polymers 0.000 claims description 4
- 239000004416 thermosoftening plastic Substances 0.000 claims description 4
- 239000008240 homogeneous mixture Substances 0.000 claims description 2
- 239000011148 porous material Substances 0.000 description 33
- 239000012528 membrane Substances 0.000 description 32
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 22
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 10
- 239000004926 polymethyl methacrylate Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000004626 scanning electron microscopy Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000007493 shaping process Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical class OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical class CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical group CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- JRXXEXVXTFEBIY-UHFFFAOYSA-N 3-ethoxypropanoic acid Chemical class CCOCCC(O)=O JRXXEXVXTFEBIY-UHFFFAOYSA-N 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000589149 Azotobacter vinelandii Species 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 241000252867 Cupriavidus metallidurans Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical class [H]O* 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- -1 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
Description
【発明の詳細な説明】
産業上の利用分野
本発明は、3−ヒドロキシ酪酸単位を主成分と
する熱可塑性ポリエステルからなる微多孔質膜の
製造法に関する。
近年、高分子材料による多孔質膜の研究開発が
活発に行なわれ、平膜及び中空繊維膜などの形態
に成形された多孔質膜は透析、過、ガス交換等
に広く応用されている。特に、医療分野では、人
工腎臓、人工肝臓、血漿交換療法、人工肺として
その利用は急速に拡大しつつある。これらの医療
用途に関して要求される膜の代表的性能として、
生体適合性および抗凝血性が挙げられる。生体適
合性は、例えば体内植込み型の人工臓器を開発す
る場合に欠くべからざる要因であり、抗凝血性は
ヘパリン等の抗凝血剤の使用を極力抑えることを
可能にする。従つて、現在、生体適合性があり、
且つ抗凝血性に優れた素材の探索が急務とされて
いる。
一方、人工腎臓、血漿交換療法等の医療用分野
での微多孔質膜に要求されるもう一つの重要な特
性に、膜の平均孔径及び孔径分布の均一化並びに
孔の形状のコントロールが挙げられる。例えば、
血漿交換療法では、血液中の血球とγ−グロブリ
ンを効率良く分離する必要があり、その為には平
均孔径、孔径分布および孔形状のコントロールが
必須条件となつてくる。
発明が解決しようとする問題点
本発明者等は、上述のような状況に鑑み、生体
適合性を有し、孔凝血性に優れた3−ヒドロキシ
酪酸を主成分とする素材を用い、その微多孔質化
に際し、平均孔径及び孔径分布の均一なしかも孔
形状のコントロールされた膜を得ることに成功
し、本発明を完成することが出来た。
問題点を解決するための手段
即ち、本発明に係る微多孔質膜の製造法は、3
−ヒドロキシ酪酸単位を80モル%以上含む熱可塑
性ポリエステルと、少なくとも一種類以上の物質
からなる第二成分との混合物から、第二成分中の
少なくとも一種類の物質を除去することを特徴と
する。
以下、本発明の微多孔質膜の製造法を詳しく説
明する。
本発明の製造法において膜素材として用いる成
分は、3−ヒドロキシ酪酸単位
を基本繰り返し単位とする脂肪族ポリエステル、
即ち、ポリヒドロキシブチレート(以下、
「PHB」と略す)である。本発明で用いるPHB
は、その繰り返し単位の80モル%以上が3−ヒド
ロキシ酪酸単位である。PHBは主に微生物によ
つて合成され、アイソタクチツクな光学活性を有
する結晶性ポリマーで、178℃近辺に明確な結晶
の融点を示す。
PHBを微生物の培養法によつて製造する場合、
例えば微生物アルカリゲネス・ユートロフス、ア
ゾトバクター・ビネランデイなどをグルコースに
より培養すると、ある期間生物内にPHBが生産
される。更に、このグルコースと共にプロピオン
酸、3−ヒドロキシプロピオン酸、3−エトキシ
プロピオン酸、2−ヒドロキシ酪酸、イソ酪酸、
アクリル酸等を使用することによつて、3−ヒド
ロキシ酪酸単位()の他に下記繰返し単位
()を含む熱可塑性脂肪酸ポリエステルを得る
ことができる。
() −O・CH(CH3)・CH2CO−
() −O・CR1R2・(CR3R4)o・CO−
上式において、nは0又は1以上の整数、R1、
R2、R3、R4はそれぞれ水素、炭化水素基、ヒド
ロキシ置換炭化水素基又はヒドロキシ基である。
ただし、n=1そしてR2=R3=R4=Hであると
きは、R1はメチル基でないものとする。
PHBの分子量は微生物培養条件によつて変化
し、1〜200万のものが得られる。PHBと混合す
る第二成分として有機ポリマーを選ぶ場合、
PHBの分子量は膜の孔径を左右する因子となり、
分子量の大きいPHBを用いればより細かい孔径
の膜が得られる。通常、分子量1〜200万のもの
が好ましい。
第二成分としては、各種有機ポリマー、オリゴ
マーおよび粒径の均一な無機塩等を挙げることが
できるが、格別これらに限定されるものではな
い。しかしながら、第一成分と混合した後、容易
に第二成分のみを除去できるものでなければなら
ない。
有機ポリマーとしては、例えば、ポリスチレ
ン、ポリ酢酸ビニル、ポリメタクリル酸メチル、
ポリ塩化ビニル、ポリカーボネート、ポリ塩化ビ
ニリデン、ポリビニルアセテート、エチルセルロ
ース、ポリエチレンテレフタレート、ニトロセル
ロース、酢酸セルロース、ポリビニルアルコー
ル、ポリアミド、ポリアクリロニトリル等を挙げ
ることができる。これらのオリゴマーも用いるこ
とができ、無機塩としては、例えば、塩化ナトリ
ウム、塩化カルシウム、硫酸ナトリウム、硫酸ア
ンモニウム、炭酸ナトリウム、硝酸ナトリウム、
シユウ酸アンモニウム、酒石酸カリウム等を挙げ
ることができる。
微多孔質膜の孔径分布を2種類以上存在させた
い場合には第二成分を2種類以上用いることがで
きる。第二成分として有機ポリマーを用いる場
合、その分子量は膜の孔径を左右する因子とな
り、分子量の大きいものは大きい孔径の膜を与え
る。通常、1000〜200万のものが好ましい。
第二成分として有機ポリマーを用いる場合、第
一成分であるPHBとの混和性に富むものは好ま
しくない。特に、第二成分としては非晶性ポリマ
ー或は結晶性の低いポリマーを用いることが好ま
しい。
膜の形態としては、フイルム状、中空繊維状、
チユーブ状、いずれの形態とするかはその用途に
よつて異なるが、本発明ではいずれの形態でも作
ることが可能である。血液の過や透析を目的と
した医療用途に向ける膜は、中空繊維状であるこ
とが好ましい。
高分子材料から多孔質膜を得るには高分子を溶
剤に溶解させて製膜原液を調製し、賦形後、脱溶
剤する方法(湿式法、乾式法)、及びポリマーを
その結晶融点以上に加熱溶融し適切なダイス或は
ノズルより押し出し冷却固化させる溶融法がある
が、本発明では、いずれの方法を採ることも可能
である。
上記湿式法、乾式法、溶融法いずれの場合で
も、第一成分と第二成分を溶解または溶融状態で
混合することが好ましい。第二成分が溶解できな
い場合には、第一成分のみ溶解し混合する。第二
成分が有機ポリマーの場合、第一成分である
PHBと同一の溶媒で溶解させることが好ましく、
良溶媒としてクロロホルム、トリフルオルエタノ
ール等が挙げられる。
第一成分と第二成分の混合比は、膜の空孔率を
左右する因子で、通常第二成分の量の多いものは
空孔率が大きい。
フイルム状或は中空繊維状に賦形する際、第二
成分群に有機ポリマーを用いる場合、湿式法、乾
式法では脱溶媒速度が、また溶融法では冷却速度
が膜の孔径を作用する因子となる。通常、速度の
速いものが孔径が細かくなる。
賦形段階で第一成分であるPHBは結晶化を起
すが、熱処理、延伸によつて更に結晶化を促進す
ることが好ましい。結晶化温度は50℃以上、融点
以下が好ましい。
次いで、第一成分と第二成分との均一混合物か
ら第二成分を除去するが、第一成分に影響が少な
く、第二成分中の少なくとも一種類を除去できる
方法であれば、どのような方法でも良い。例え
ば、無機塩等であれば、水、酸、塩基、有機溶剤
で抽出する方法、第二成分が揮発性であれば加熱
による方法等第二成分の性質に応じて適当な方法
を選択することができる。特に、第一成分を溶解
しない溶媒を用いる方法は、有効である。第二成
分に有機ポリマーを用いる場合は、第一成分であ
るPHBがクロロホルム等の特定の溶媒にしか溶
解しにくいことから、第二成分を除去する溶媒を
容易に見出し得る。
第二成分を除去して得られた微多孔質膜を更に
熱処理、延伸して形態安定性、機械的性能の向上
を計ることは好ましい。
斯くして得られた微多孔質膜は透水速度が0.01
〜50/m2hrmmHgの値を有することから、空孔
は互に連結し、過膜としての性能を示すことが
わかる。PHBは微生物によつて容易に分解され
るため、本発明によつて得られる微多孔質膜は限
外過膜などの用途以外に、チユーブ状に賦形す
ることにより人工血管や気管として、またフイル
ム状に賦形することにより熱傷カバー材としての
用途に、さらに、薬材を含んだ球状に賦形するこ
とにより徐法性を有する薬として用いることが出
来る。
実施例
以下、実施例について本発明をより具体的に説
明する。
実施例 1
アゾトバクター・ビネランデー(Azotobacter
vinelandi)IFO13581と脱イオン水1当り次の
組成を有する培地7を含む10容積の醗酵槽で
PH7.7、30℃において72時間好気培養を行い、増
殖させた。
グルコース 3重量/容量%
K2HPO4 0.1
CaCl2 0.11
MgSo4・7H2O 0.4
FeSO4・7H2O 0.012
(HH4)6Mo7O244H2O 0.01
NaCl 0.4
CaCO3 0.01
ZnO 0.002
MnCl・4H2O 0.01
CuCl4・4H2O 0.001
CaCl2・6H2O 0.001
培養後、培養液と遠心分離(6000rpm)によつ
て菌体を分離し、更に脱イオン水およびアセトン
で洗浄し、遠心分離操作を繰り返し80gの菌体を
得た。
この菌体を3のクロロホルム中に懸濁させ、
4時間煮沸した。菌体を過し、その液を6
のn−ヘキサン中に注ぎ、凝固物を分離し、乾燥
させ32gの白色粉末を得た。
この粉末は元素分析、NMRおよびIRによる分
析の結果純粋なPHBであることが確認された。
以上のように合成されたPHBをクロロホルム
に溶解して2.5重量%溶液を作成した。一方、第
二成分としてポリメタクリル酸メチル(PMMA)
の重量平均分子量(Mw)が、それぞれMw=
5000、2.8万、9.5万、27万、100万のものをクロ
ロホルムに溶解して2.5重量%溶液を作成した。
第一成分(PHB)と第二成分(PMMA)をそれ
ぞれ混合比1:1で混合撹拌した後、ガラス板上
に流延し、クロロホルムを一定速度で蒸発させて
膜厚約60μmのフイルムを得た。このフイルムを
ジメチルホルムアミド(DMF)中に浸漬し、
PMMAのみを除去した後、流水で洗浄・乾燥し
た。乾燥の際、PMMAのMw=2.8万から得られ
た膜につき、150℃、30分間熱処理した。得られ
た膜はいずれも均一な白色を呈していた。
第1図および第2図として、PHBと第二成分
PMMA(Mw=2.8万)から得られた膜のそれぞれ
3000倍および7000倍走査型電子顕微鏡(SEM)
写真を示す。これらの写真から、本発明の効果が
容易に理解できる。即ち、本発明方法により得ら
れる微多孔質膜における平均孔径及び孔径分布の
均一度が高く、且つ孔形状がよくコントロールさ
れたものであることが観察できる。また、実質的
に円形の均一な孔径のものが得られている。この
ようにして得られた膜のSEM写真から読み取つ
た平均孔径及びその変動率、更に膜の透水速度を
第1表に示した。ただし、孔径の変動率は次式に
従つて計算した。
RiはSEM写真より読み取つた個々の孔径であ
り、はその算術平均値、nは個数で100個とし
た。これよりPMMAの分子量の大きいものを使
用すれば大きい孔径の膜が得られ、また孔径も良
く整つたものであることがわかる。更に、これら
の透水速度が0.01〜50/m2・hr・mmHgの値を
示すことから空孔は互に連結し、過膜としての
性能を示すことが明らかである。
実施例 2
実施例1と同様に作成されたPHBと分子量2.8
万のPMMAパウダーとを、混合比が1:1とな
るように調合し、表面温度185℃の熱板上で溶融
混合した。その後、自然冷却し、ジメチルホルム
アミド中に浸漬後、流水で洗浄した。このように
して得られた膜の孔径、その変動率及び透水速度
を第1表に示す。実施例1と同様に孔径が均一で
空孔が互に連結した膜が得られた。
実施例 3
実施例1と同様に合成したPHBをクロロホル
ムに溶解し、2.5重量%溶液を作成した。第二成
分群として無水塩化カルシウム(CaCl2)をクロ
ロホルム/エチルアルコールの8/2の混合溶媒に
溶解し、2.5重量%溶液を調製した。更に、この
溶液をガラスフイルターG−2を用いて過し
た。これら第一成分と第二成分とを混合比1:1
で混合撹拌し、ガラス板上に流延した後、溶媒を
蒸発させて膜厚約40μmのフイルムを得た。次
に、このフイルムをエチルアルコール中に浸漬
し、CaCl2のみを除去し均一に白化した膜を得
た。この膜のSEM写真から読み取つた平均孔径
及びその変動率、ならびに膜の透水速度を第1表
に示す。
【表】DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to a method for producing a microporous membrane made of a thermoplastic polyester containing 3-hydroxybutyric acid units as a main component. In recent years, research and development of porous membranes made of polymeric materials has been actively conducted, and porous membranes formed in the form of flat membranes, hollow fiber membranes, etc. are widely applied to dialysis, filtration, gas exchange, etc. In particular, in the medical field, its use as artificial kidneys, artificial livers, plasma exchange therapy, and artificial lungs is rapidly expanding. The typical performance of membranes required for these medical applications is as follows:
biocompatibility and anticoagulant properties. Biocompatibility is an indispensable factor, for example, when developing artificial organs to be implanted in the body, and anticoagulability makes it possible to minimize the use of anticoagulants such as heparin. Therefore, it is currently biocompatible;
In addition, there is an urgent need to search for materials with excellent anticoagulant properties. On the other hand, another important characteristic required of microporous membranes in medical fields such as artificial kidneys and plasma exchange therapy is the uniformity of the membrane's average pore diameter and pore size distribution, as well as control of the pore shape. . for example,
In plasma exchange therapy, it is necessary to efficiently separate blood cells and γ-globulin in blood, and for this purpose, control of average pore size, pore size distribution, and pore shape is essential. Problems to be Solved by the Invention In view of the above-mentioned circumstances, the present inventors have developed a material whose main component is 3-hydroxybutyric acid, which is biocompatible and has excellent pore coagulability. Upon making the membrane porous, we were able to successfully obtain a membrane with a uniform average pore size and pore size distribution, as well as a controlled pore shape, thereby completing the present invention. Means for solving the problems That is, the method for producing a microporous membrane according to the present invention is as follows:
- It is characterized in that at least one substance in the second component is removed from a mixture of a thermoplastic polyester containing 80 mol% or more of hydroxybutyric acid units and a second component consisting of at least one substance. Hereinafter, the method for producing a microporous membrane of the present invention will be explained in detail. The component used as a membrane material in the production method of the present invention is a 3-hydroxybutyric acid unit. aliphatic polyester whose basic repeating unit is
That is, polyhydroxybutyrate (hereinafter referred to as
(abbreviated as “PHB”). PHB used in the present invention
80 mol% or more of its repeating units are 3-hydroxybutyric acid units. PHB is mainly synthesized by microorganisms, is a crystalline polymer with isotactic optical activity, and exhibits a clear crystalline melting point around 178°C. When PHB is manufactured by a microbial culture method,
For example, when microorganisms such as Alcaligenes eutrophus and Azotobacter vinellandii are cultured with glucose, PHB is produced within the organisms for a certain period of time. Furthermore, along with this glucose, propionic acid, 3-hydroxypropionic acid, 3-ethoxypropionic acid, 2-hydroxybutyric acid, isobutyric acid,
By using acrylic acid or the like, a thermoplastic fatty acid polyester containing the following repeating unit () in addition to the 3-hydroxybutyric acid unit () can be obtained. () −O・CH(CH 3 )・CH 2 CO− () −O・CR 1 R 2・(CR 3 R 4 ) o・CO− In the above formula, n is 0 or an integer of 1 or more, R 1 ,
R 2 , R 3 , and R 4 are each hydrogen, a hydrocarbon group, a hydroxy-substituted hydrocarbon group, or a hydroxy group.
However, when n=1 and R 2 =R 3 =R 4 =H, R 1 is not a methyl group. The molecular weight of PHB varies depending on the microbial culture conditions, and can be obtained in the range of 1 to 2 million. When choosing an organic polymer as the second component to mix with the PHB,
The molecular weight of PHB is a factor that influences the pore size of the membrane.
If PHB with a large molecular weight is used, a membrane with a finer pore size can be obtained. Generally, a molecular weight of 1 to 2 million is preferred. Examples of the second component include various organic polymers, oligomers, and inorganic salts with uniform particle size, but are not particularly limited to these. However, it must be possible to easily remove only the second component after mixing with the first component. Examples of organic polymers include polystyrene, polyvinyl acetate, polymethyl methacrylate,
Examples include polyvinyl chloride, polycarbonate, polyvinylidene chloride, polyvinyl acetate, ethyl cellulose, polyethylene terephthalate, nitrocellulose, cellulose acetate, polyvinyl alcohol, polyamide, polyacrylonitrile, and the like. These oligomers can also be used, and examples of inorganic salts include sodium chloride, calcium chloride, sodium sulfate, ammonium sulfate, sodium carbonate, sodium nitrate,
Examples include ammonium oxalate and potassium tartrate. If it is desired that the microporous membrane has two or more types of pore size distribution, two or more types of the second component can be used. When an organic polymer is used as the second component, its molecular weight is a factor that influences the pore size of the membrane, with higher molecular weights providing membranes with larger pore sizes. Usually, 10 to 2 million is preferable. When using an organic polymer as the second component, it is not preferable to use an organic polymer that is highly miscible with PHB, which is the first component. In particular, it is preferable to use an amorphous polymer or a polymer with low crystallinity as the second component. The form of the membrane is film-like, hollow fiber-like,
The shape of a tube or the like differs depending on its use, but in the present invention, any shape can be produced. Membranes intended for medical applications for blood filtering and dialysis are preferably in the form of hollow fibers. To obtain a porous membrane from a polymer material, there are two methods: dissolve the polymer in a solvent to prepare a film-forming stock solution, form it, remove the solvent (wet method, dry method), and heat the polymer to a temperature higher than its crystal melting point. There is a melting method in which the material is heated and melted, extruded through an appropriate die or nozzle, and cooled and solidified, but any method can be used in the present invention. In any of the above wet methods, dry methods, and melting methods, it is preferable to mix the first component and the second component in a dissolved or molten state. If the second component cannot be dissolved, only the first component is dissolved and mixed. If the second component is an organic polymer, the first component
It is preferable to dissolve it in the same solvent as PHB,
Examples of good solvents include chloroform and trifluoroethanol. The mixing ratio of the first component and the second component is a factor that influences the porosity of the membrane, and normally the membrane with a large amount of the second component has a large porosity. When forming into a film or hollow fiber, when an organic polymer is used as the second component group, the desolvation rate is a factor that affects the pore size of the membrane in the wet method or dry method, and the cooling rate in the melt method. Become. Generally, the faster the speed, the smaller the pore size. Although PHB, which is the first component, crystallizes in the shaping step, it is preferable to further promote crystallization by heat treatment and stretching. The crystallization temperature is preferably 50°C or higher and lower than the melting point. Next, the second component is removed from the homogeneous mixture of the first component and the second component, but any method can be used as long as it has little effect on the first component and can remove at least one of the second components. But it's okay. For example, in the case of an inorganic salt, an appropriate method should be selected depending on the nature of the second component, such as extraction with water, acid, base, or organic solvent, or heating if the second component is volatile. I can do it. In particular, a method using a solvent that does not dissolve the first component is effective. When using an organic polymer for the second component, it is easy to find a solvent that removes the second component, since PHB, the first component, is only easily soluble in a specific solvent such as chloroform. It is preferable to further heat-treat and stretch the microporous membrane obtained by removing the second component to improve shape stability and mechanical performance. The microporous membrane thus obtained has a water permeation rate of 0.01
The value of ~50/m 2 hrmmHg indicates that the pores are interconnected and exhibits performance as a membrane. Since PHB is easily decomposed by microorganisms, the microporous membrane obtained by the present invention can be used not only as an ultrafiltration membrane but also as an artificial blood vessel or trachea by shaping it into a tube. By shaping it into a film, it can be used as a burn covering material, and by shaping it into a sphere containing a medicinal material, it can be used as a medicine with slow-release properties. Examples Hereinafter, the present invention will be described in more detail with reference to Examples. Example 1 Azotobacter vinelandii
vinelandi) IFO 13581 and 7 volumes of medium with the following composition per 1 part of deionized water:
Aerobic culture was performed for 72 hours at PH7.7 and 30°C to proliferate. Glucose 3% by weight/volume K 2 HPO 4 0.1 CaCl 2 0.11 MgSo 4・7H 2 O 0.4 FeSO 4・7H 2 O 0.012 (HH 4 ) 6 Mo 7 O 24 4H 2 O 0.01 NaCl 0.4 CaCO 3 0.01 ZnO 0.002 MnCl・4H 2 O 0.01 CuCl 4・4H 2 O 0.001 CaCl 2・6H 2 O 0.001 After culturing, the bacterial cells were separated from the culture medium by centrifugation (6000 rpm), further washed with deionized water and acetone, and centrifuged. The operation was repeated to obtain 80 g of bacterial cells. This bacterial body was suspended in chloroform from step 3,
Boiled for 4 hours. Strain the bacterial cells and pour the liquid into 6
of n-hexane, the coagulum was separated and dried to obtain 32 g of white powder. This powder was confirmed to be pure PHB by elemental analysis, NMR, and IR analysis. PHB synthesized as described above was dissolved in chloroform to prepare a 2.5% by weight solution. Meanwhile, polymethyl methacrylate (PMMA) as the second component
The weight average molecular weight (M w ) of M w =
5000, 28,000, 95,000, 270,000, and 1 million were dissolved in chloroform to create a 2.5% by weight solution.
After mixing and stirring the first component (PHB) and the second component (PMMA) at a mixing ratio of 1:1, they were cast onto a glass plate, and chloroform was evaporated at a constant rate to obtain a film with a thickness of approximately 60 μm. Ta. This film was immersed in dimethylformamide (DMF),
After removing only PMMA, it was washed with running water and dried. During drying, the film obtained from PMMA with Mw = 28,000 was heat treated at 150°C for 30 minutes. All of the obtained films exhibited a uniform white color. As Figures 1 and 2, PHB and the second component
Each of the membranes obtained from PMMA (M w = 28,000)
3000x and 7000x scanning electron microscopy (SEM)
Show photos. The effects of the present invention can be easily understood from these photographs. That is, it can be observed that the microporous membrane obtained by the method of the present invention has a high degree of uniformity in average pore size and pore size distribution, and has a well-controlled pore shape. Also, substantially circular pores of uniform diameter have been obtained. Table 1 shows the average pore diameter and its fluctuation rate, as well as the water permeation rate of the membrane, as determined from the SEM photograph of the membrane thus obtained. However, the rate of variation in pore diameter was calculated according to the following formula. R i is the individual pore diameter read from the SEM photograph, is the arithmetic mean value thereof, and n is the number of pores, which is 100. This shows that if PMMA with a large molecular weight is used, a membrane with a large pore size can be obtained, and the pore size is also well arranged. Furthermore, since these water permeation rates show values of 0.01 to 50/m 2 ·hr · mmHg, it is clear that the pores are interconnected and exhibit performance as a membrane. Example 2 PHB prepared in the same manner as Example 1 and molecular weight 2.8
1,000 of PMMA powder were mixed at a mixing ratio of 1:1, and melted and mixed on a hot plate with a surface temperature of 185°C. Thereafter, it was naturally cooled, immersed in dimethylformamide, and then washed with running water. Table 1 shows the pore diameter, its fluctuation rate, and water permeation rate of the membrane thus obtained. As in Example 1, a membrane with uniform pore diameter and interconnected pores was obtained. Example 3 PHB synthesized in the same manner as in Example 1 was dissolved in chloroform to create a 2.5% by weight solution. As a second component group, anhydrous calcium chloride (CaCl 2 ) was dissolved in an 8/2 mixed solvent of chloroform/ethyl alcohol to prepare a 2.5% by weight solution. Furthermore, this solution was filtered using a glass filter G-2. The mixing ratio of these first and second components is 1:1.
After mixing and stirring and casting on a glass plate, the solvent was evaporated to obtain a film with a thickness of about 40 μm. Next, this film was immersed in ethyl alcohol to remove only CaCl 2 and obtain a uniformly whitened film. Table 1 shows the average pore diameter and its fluctuation rate as read from the SEM photograph of this membrane, as well as the water permeation rate of the membrane. 【table】
第1図はPHBとPMMAとの混合物から得られ
た微多孔質膜の走査型電子顕微鏡(SEM)写真
(3000倍)であり、第2図は同じ膜のSEM写真
(5000倍)である。
Figure 1 is a scanning electron microscope (SEM) photograph (3000x) of a microporous membrane obtained from a mixture of PHB and PMMA, and Figure 2 is a SEM photograph (5000x) of the same membrane.
Claims (1)
熱可塑性ポリエステルと、少なくとも一種類以上
の物質からなる第二成分との均一混合物を賦形
し、次いで第二成分中の少なくとも一種類の物質
を除去することを特徴とする微多孔質膜の製造
法。 2 第一成分を溶解しない溶媒で、第二成分中の
少なくとも一種類の物質を溶解除去することを特
徴とする特許請求の範囲第1項記載の製造法。 3 第二成分が少くとも一種類の有機ポリマーか
らなることを特徴とする特許請求の範囲第1項ま
たは第2項記載の製造法。 4 透水速度が0.01〜50/m2・hr・mmHgであ
る微多孔質膜を製造する特許請求の範囲第1項、
第2項または第3項記載の製造法。[Scope of Claims] 1. A homogeneous mixture of a thermoplastic polyester containing 80 mol% or more of 3-hydroxybutyric acid units and a second component consisting of at least one substance is shaped, and then at least one of the second components A method for producing a microporous membrane characterized by removing one type of substance. 2. The manufacturing method according to claim 1, wherein at least one substance in the second component is dissolved and removed using a solvent that does not dissolve the first component. 3. The manufacturing method according to claim 1 or 2, wherein the second component consists of at least one type of organic polymer. 4. Claim 1, which produces a microporous membrane having a water permeation rate of 0.01 to 50/m 2 ·hr · mmHg;
The manufacturing method according to item 2 or 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59127279A JPS618107A (en) | 1984-06-22 | 1984-06-22 | Production of microporous membrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59127279A JPS618107A (en) | 1984-06-22 | 1984-06-22 | Production of microporous membrane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS618107A JPS618107A (en) | 1986-01-14 |
| JPH0470939B2 true JPH0470939B2 (en) | 1992-11-12 |
Family
ID=14956044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59127279A Granted JPS618107A (en) | 1984-06-22 | 1984-06-22 | Production of microporous membrane |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS618107A (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8802414D0 (en) * | 1988-06-27 | 1988-06-28 | Astra Meditec Ab | NEW SURGICAL MATERIAL |
| US5480394A (en) * | 1991-09-27 | 1996-01-02 | Terumo Kabushiki Kaisha | Flexible member for use as a medical bag |
| CH684273A5 (en) * | 1992-02-25 | 1994-08-15 | Weidmann H Ag | Porous dimensionally stable body. |
| ES2281147T3 (en) | 1997-12-22 | 2007-09-16 | Metabolix, Inc. | COMPOSITIONS OF POLYHYDROXIALCANOATE WITH CONTROLLED DEGRADATION RATES. |
| CN1946783B (en) * | 2004-04-23 | 2012-01-25 | Ntn株式会社 | Resin porous body and manufacturing method thereof |
| WO2007086306A1 (en) * | 2006-01-30 | 2007-08-02 | Kinki University | Biodegradable inverted-opal structure, method for production of the same, use of the same, and medical implant comprising the same |
-
1984
- 1984-06-22 JP JP59127279A patent/JPS618107A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS618107A (en) | 1986-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2080819A (en) | Polymethyl methacrylate membrane | |
| US9902939B2 (en) | Device for renal cell expansion | |
| EP1165749A1 (en) | Method for preparing porous, biodegradable and biocompatible, polymeric scaffolds for tissue engineering | |
| CN102634865B (en) | Medical tube material with adjustable degradation time and preparation method thereof | |
| EP0066408B1 (en) | Porous membrane | |
| US7151120B2 (en) | Degradable porous materials with high surface areas | |
| JP2009538940A (en) | Porous membranes containing biocompatible block-copolymers | |
| JPS6097001A (en) | Polyvinylidene fluoride porous membrane and its preparation | |
| JPH0470939B2 (en) | ||
| JPH04326932A (en) | Polyester porous film | |
| JP6717459B2 (en) | Nanofiber manufacturing method | |
| JPH06336523A (en) | Polyester moldings | |
| CN1047317A (en) | porous article | |
| JPH02109570A (en) | Silk fibroin-containing molded product | |
| JPH0278425A (en) | Hydrophilic and dryable semipermeable membrane based on polyvinylidene fluoride | |
| JPS60137402A (en) | Membrane with microfine pore | |
| US6979700B2 (en) | Non-degradable porous materials with high surface areas | |
| KR100499096B1 (en) | Fabrication method of porous polymeric scaffolds for tissue engineering application | |
| CN113753933B (en) | Fucoidan/calcium carbonate hybrid nanorod and preparation method thereof | |
| JPS5967964A (en) | Hollow fiber useful for blood treatment | |
| EP0181410A1 (en) | Hollow fiber membrane for dialysis of blood | |
| JPH0536065B2 (en) | ||
| CN1255189C (en) | Prepn of anticoagulant insoluble silk protein material | |
| JPS5958041A (en) | Method for manufacturing polysulfone porous membrane | |
| JPS61283304A (en) | Semipermeable membrane and its manufacture |